| |
|
|
|
Kunwar Shailubhai, Ph.D. & M.B.A.
Kunwar Shailubhai, Ph.D. & M.B.A., is Executive Vice President
and Head of Research and Development of Callisto Pharmaceuticals. From 2001
to April 2003,
Dr. Shailubhai was Vice President, Drug Discovery at Synergy Pharmaceuticals,
where he was chiefly responsible for the development of Synergy’s GCRA
agonist program for drugs to treat colon cancer. Dr. Shailubhai has been working
in the area of cancer and inflammatory diseases for nearly 15 years. At Monsanto
Company from 1993 to 2000, he was Group Leader of the cancer chemoprevention
group and worked on a number of projects in cancer research including inhibitors
of metalloproteinases, cyclooxygenase-1&2, and 5-lipoxygenase as anti-tumor
agents. He also initiated and developed a project on applications
of COX-2 selective inhibitors (CELEBREX®) for inhibition of angiogenesis and for induction
of apoptosis
in xenografts of human prostate cancer cell lines in nude mice. Recently, he conceived a novel hypothesis on prevention and
control
of primary colon cancer by human uroguanylin, and demonstrated that
the oral administration of human uroguanylin (16 amino acid peptide) inhibits
polyp
formation in Apc min/+ by inducing apoptosis in intestinal epithelium.
This research invention received national recognition and press coverage by
the
Cancer Foundation of America. Dr. Shailubhai has extensive experience and knowledge
in various biochemical mechanisms leading to the process of carcinogenesis.
He previously
served as a Senior Staff Fellow at the National Institutes of Health
and an Assistant Professor at the University of Maryland. Dr. Shailubhai holds
3
patents and has 36 publications in peer-reviewed scientific journals.
He earned is Ph.D. in Microbiology in 1984, followed by a post-doctoral fellowship
at
the University of Maryland at College Park, Maryland. Dr. Shailubhai
received an M.B.A. with special emphasis on executive management and
business development.
|
|
|
|
|
